tiprankstipranks
PureTech Health PLC (GB:PRTC)
LSE:PRTC

PureTech Health (PRTC) Share Price & Analysis

1 Followers

PRTC Stock Chart & Stats

Day’s Range0p - 0p
52-Week Range139.00p - 242.93p
Previous Close202p
Volume8.58K
Average Volume (3M)589.55K
Market Cap
£545.30M
Enterprise Value309.97M
Total Cash (Recent Filing)$350.10M
Total Debt (Recent Filing)$46.87M
Price to Earnings (P/E)-15.5
Beta1.51
Apr 25, 2024
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding273,866,153
10 Day Avg. Volume252,708
30 Day Avg. Volume589,552
Standard Deviation0.10
R-Squared0.12
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.36
Price to Sales (P/S)11736.67
Price to Cash Flow (P/CF)-477.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit19.85
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

8.98%11.52%3.50%75.99%
3.50% Other Institutional Investors
75.99% Public Companies and
Individual Investors

PRTC FAQ

What was PureTech Health PLC’s price range in the past 12 months?
PureTech Health PLC lowest share price was 139.00p and its highest was 242.93p in the past 12 months.
    What is PureTech Health PLC’s market cap?
    Currently, no data Available
    When is PureTech Health PLC’s upcoming earnings report date?
    PureTech Health PLC’s upcoming earnings report date is Apr 25, 2024 which is in 51 days.
      How were PureTech Health PLC’s earnings last quarter?
      PureTech Health PLC released its earnings results on Aug 29, 2023. The company reported -0.071p earnings per share for the quarter, missing the consensus estimate of -0.002p by -0.069p.
        Is PureTech Health PLC overvalued?
        According to Wall Street analysts PureTech Health PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does PureTech Health PLC pay dividends?
          PureTech Health PLC does not currently pay dividends.
          What is PureTech Health PLC’s EPS estimate?
          PureTech Health PLC’s EPS estimate is -£0.26.
            How many shares outstanding does PureTech Health PLC have?
            PureTech Health PLC has 269,949,740 shares outstanding.
              What happened to PureTech Health PLC’s price movement after its last earnings report?
              PureTech Health PLC reported an EPS of -0.071p in its last earnings report, missing expectations of -0.002p. Following the earnings report the stock price went up 3.987%.
                Which hedge fund is a major shareholder of PureTech Health PLC?
                Currently, no hedge funds are holding shares in GB:PRTC
                ---

                PureTech Health Stock Smart Score

                4
                Neutral
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                -8.18%
                12-Months-Change

                Fundamentals

                Return on Equity
                -8.84%
                Trailing 12-Months
                Asset Growth
                -19.52%
                Trailing 12-Months

                Company Description

                PureTech Health PLC

                PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on areas of growing scientific and technical insights that it believes are at an important inflection point, including the central nervous, gastrointestinal and immune systems, and the interactions and signaling between them. The company has a robust pipeline of advanced programs that are post-human proof of concept, focused on addressing some of the society's healthcare needs.
                ---

                PRTC Stock 12 Months Forecast

                Average Price Target

                {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"71":"71p","143":"143p","215":"215p","287":"287p","-1":"-1p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,71,143,215,287],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2022","6":"Feb<br/>2023","9":"May<br/>2023","12":"Jul<br/>2023","25":"Jul<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,215.5,198.92307692307693,182.34615384615384,165.76923076923077,149.19230769230768,132.6153846153846,116.03846153846155,99.46153846153847,82.88461538461539,66.30769230769232,49.730769230769226,33.15384615384616,16.576923076923094,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,215.5,198.92307692307693,182.34615384615384,165.76923076923077,149.19230769230768,132.6153846153846,116.03846153846155,99.46153846153847,82.88461538461539,66.30769230769232,49.730769230769226,33.15384615384616,16.576923076923094,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,215.5,198.92307692307693,182.34615384615384,165.76923076923077,149.19230769230768,132.6153846153846,116.03846153846155,99.46153846153847,82.88461538461539,66.30769230769232,49.730769230769226,33.15384615384616,16.576923076923094,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":195.4,"date":1659312000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":242,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":247,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":243,"date":1667260800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":286.5,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":266.5,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":246.5,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":220,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":221.5,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":220,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":221,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":230.5,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":215.5,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                Similar Stocks
                Company
                Price & Change
                Follow
                EKF Diagnostics Holdings
                Futura Medical
                Genedrive
                C4X Discovery Holdings

                Best Analysts Covering PRTC

                1 Year
                Peter WelfordJefferies
                1 Year Success Rate
                2/9 ratings generated profit
                22%
                1 Year Average Return
                -6.89%
                reiterated a buy rating 10 months ago
                Copying Peter Welford's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -6.89% per trade.
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis